Tecan Group AG · SIX:TECN
Tecan — SLAS 2023
29 slides from Tecan's conference presentation, Feb 27, 2023
Slide 1: USO
. nf USO a ~ « *
Slide 2: Automated production of spheroids by magnetic cell assembly for drug response profiling
Automated production of spheroids by magnetic cell assembly for drug response profiling Michael Nosswitz Application Specialist Cellomics 27.02.2023
Slide 3: 3D cell models in drug development; Magnetic 3D bioprinting; Key take-home messages
3D cell models in drug development Magnetic 3D bioprinting Manufacture 3D spheroids : From benchtop to automated solution Key take-home messages 3
Slide 4: Importance of 3D cell models for drug development
Importance of 3D cell models for drug development .. advanced 3D cell models -> reduce the overall R&D cost › <10% of the anticancer drugs that enter the clinical trials reach the market Consistency › Inefficient preclinical models spheroids › Low predictiveness and Scalability high failure rates as
Slide 5: Magnetic 3D Bioprinting
Magnetic 3D Bioprinting Magnetizing Cells NanoShuttle™-PL Bioprinting High-throughput Smaller Samples Automation Incubation Cells Detach and Incubation seed cells Magnetized Cells Magnet Bottom Souza et al. Nature Nanotechnology, April 2010 Timm et al. Scientific Reports, October 2013 5
Slide 6: Steps in 3D cell model generation for drug testing
Steps in 3D cell model generation for drug testing .. from benchtop solution to an automated workflow Pre-test and optimize Increase throughput Automate ▪ Cell number determination ▪ Cell number determination ▪ Cell seeding with Fluent® in 96-well plate in 384-well plate ▪ Drug dispensing with ▪ QC
Slide 7: Steps in 3D cell model generation for drug testing
Steps in 3D cell model generation for drug testing .. from benchtop solution to an automated workflow Pre-test and optimize Increase throughput Automate ▪ Cell number determination ▪ Cell number determination ▪ Cell seeding with Fluent in 96-well plate in 384-well plate ▪ Drug dispensing with ▪ QC a
Slide 8: Workflow to generate spheroids in flat bottom plates
Workflow to generate spheroids in flat bottom plates .. in a benchtop solution Magnetizing cells Cell seeding Spheroid formation Drug treatment Readout • BF imaging for QC • BF and Fl Imaging 96-well overnight 1 day 1-3 days 384-well HeLa cells … 4-6 days from magnetization to readout 8
Slide 9: Spark Cyto is a powerful tool for multiplexing
Spark Cyto is a powerful tool for multiplexing .. combine Multi-mode reader capabilities with brightfield and fluorescence imaging UV/VIS Absorbance Live cell imaging Fluorescence Cell incubation Luminescence Injector Spark Cyto is for Research Use Only. Not for use in diagnostic procedures. 9
Slide 10: Pre-testing and optimization phase requires quality control
2000 cells/well Pre-testing and optimization phase requires quality control HeLa cells in a 96-well plate 4x objective Single FOV 24 hours post seeding 5000 cells/well 10.000 cells/well 15.000 cells/well 10
Slide 11: Pre-testing and optimization phase requires quality control
2000 cells/well Pre-testing and optimization phase requires quality control HeLa cells in a 96-well plate 4x objective Single FOV 24 hours post seeding 5000 cells/well 10.000 cells/well 15.000 cells/well 11
Slide 12: Pre-testing and optimization phase requires quality control
Pre-testing and optimization phase requires quality control Generation of uniformly sized spheroids within 24 hours with M3D bioprinting Image based quality control in a controlled environment confirms homogeneous spheroids 12
Slide 13: Steps in 3D cell model generation for drug testing
Steps in 3D cell model generation for drug testing .. from benchtop solution to an automated workflow Pre-test and optimize Increase throughput Automate ▪ Cell number determination ▪ Cell number determination ▪ Cell seeding with Fluent in 96-well plate in 384-well plate ▪ Drug dispensing with ▪ QC a
Slide 14: Increase throughput through miniaturization
Increase throughput through miniaturization 96-well plate 384-well plate 2000 50 HeLa cells in a A549 cells in a 384-well plate 4x objective 10x objective Single FOV Single FOV 24 hours post seeding 100 24 hours post seeding 5000 200 10.000 1000 2000 15.000 Use for automation! 4000 14
Slide 15: Steps in 3D model generation for drug testing
Steps in 3D model generation for drug testing .. from benchtop solution to an automated workflow Pre-test and optimize Increase throughput Automate ▪ Cell number determination ▪ Cell number determination ▪ Cell seeding with Fluent in 96-well plate in 384-well plate ▪ Drug dispensing with ▪ QC and en
Slide 16: Workflow to generate spheroids in flat bottom plates
Workflow to generate spheroids in flat bottom plates .. in an automated way Magnetizing cells Cell seeding Spheroid formation Drug treatment Readout • BF imaging for QC • BF and Fl Imaging • ATP measurement 96-well (luminescence) overnight 1 day 1-3 days 384-well … 4-6 days from magnetization to rea
Slide 17: The Fluent Automation Workstation
The Fluent Automation Workstation 1 Sterile environment 4 Handle plate and tubes on deck Prevent cell culture contamination with HEPA hood 1 Fluent Finger Exchange System enables or biosafety cabinet handling of both tubes and microplates with the Robotic Gripper Arm. 2 Environmental control 5 Feed
Slide 18: The Tecan D300e Digital Dispenser
The Tecan D300e Digital Dispenser A complete package D300e digital dispenser + from pL to µL scale + direct sample addition from stock solutions + small footprint Ready-to-use cassettes + time saving + compound saving T8+ cassette D4+ cassette + DMSO and aqueous dispensing + supports 12- to 1536- we
Slide 19: Rapid dispensing of drugs ensures consistency and reliability
Rapid dispensing of drugs ensures consistency and reliability Before dispensing After dispensing D300e Digital Dispenser No disturbance of the spheroids by dispensing with D300e Example images of HeLa spheroids (cutouts) 19
Slide 20: Importance of imaging based multiplexing
Importance of imaging based multiplexing HeLa cells 10x objective Single FOV 24 hours post treatmemt 0.01µM 0.04µM 0.16µM 0.63µM 2.50µM 10µM Propidium Iodide (PI) staining Doxorubicin Gemcitabine Staurosporine CTRL 20
Slide 21: Importance of imaging based multiplexing
Importance of imaging based multiplexing HeLa cells 10x objective Single FOV 24 hours post treatmemt Inverse correlation between dead cell staining (PI) and ATP viability assay Multiplexing to further support meaningfullness of obtained results 21
Slide 22: Cell seeding and plate transfers with the Fluent
Cell seeding and plate transfers with the Fluent fully automated cell distribution and plate incubation for spheroid generation via magnetic 3D bioprinting 22
Slide 23: Drug response profiling with HeLa spheroids
Drug response profiling with HeLa spheroids Drug dispensing 72hrs CellTiter-Glo® 3D viability assay 0.5 < Z’< 1 is considered excellent Drug Gemcitabine Doxorubicin Staurosporine Topotecan Panobinostat Obatoclax Mitoxantrone Idarubicin Mitomycin Vincristine IC50 [µM] na 0.78 0.11 na 0.06 2.42 0.92 0
Slide 24: Summary
Summary … complete drug screening workflow automation with Tecan‘s equipment using M3D bioprinting approach M3D bioprinting: Fluent: • Fast cell assembly in flat • Automate liquid handling bottom microplates and plate transfers • Easy manipulation • Keep your samples sterile • Compatible with automa
Slide 25: Acknowledgements
Acknowledgements • Magdalena Eckschlager • Lucia Bruzzone • Lesley Schultz • Glauco Souza • Siegfried Sasshofer • Torsten Binder • Epifania Bono • Alexandra Oertel • Ina Albert • Beat Bornhauser • Britta Striegl 25
Slide 26: Come to see us at booth #1037
‘novation AveNEW c= mi tam: {innovation be ' = wrrenw = Gusev TECAN: | BY Brooks: haar i ts we oo ' I > =, =< J gipttighkes : a] Hig ae —s ° om = Come to see us at booth
Slide 27: www.tecan.com
Tecan – Who we are Tecan Group Ltd. makes every effort to include accurate and up-to-date information, however, it is possible that omissions or errors might have occurred. Tecan Group At Tecan we are driven to improve people’s lives and health. We do this by empowering our Ltd. cannot, therefore, m
Slide 28: TO CC
S e TO CC +. oa 7 « sy
Slide 29: Literature magnetic 3D Bioprinting
Literature magnetic 3D Bioprinting Nature Nanotechnology (2010) Neoplasia (2010) Atherosclerosis (2012) Tissue Engineering Part C: Methods (2012) Nature (2013) - Cell culture: A better brew Nature Reviews Cancer (2013) Tissue Engineering Part C: Methods (2013) Biochimica et Biophysic